BioCentury
ARTICLE | Company News

B. Twelve and Medarex in cancer deal

January 22, 2001 8:00 AM UTC

The companies will develop and market cancer therapeutics using MEDX's UltiMAb Human Antibody Development System and B. Twelve's vitamin B12-related targets. MEDX will receive license fees plus milest...